Please ensure Javascript is enabled for purposes of website accessibility

LabCorp Beats Expectations in Q1 Despite COVID-19 Drag

By Keith Speights – Apr 29, 2020 at 12:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company got off to a strong start in the first quarter but saw a big drop in diagnostic testing in the last two weeks of the quarter due to the coronavirus outbreak.

It could be a lot worse. That's probably the thought that's gone through the minds of shareholders of Laboratory Corporation of America (LH -2.21%). The stock plunged more than 30% in March. But it's now up a little year to date after a major rebound in recent weeks.

The global life sciences company announced its first-quarter results before the market opened on Wednesday. Here are the highlights from LabCorp's Q1 update.



By the numbers

LabCorp reported revenue in the first quarter of $2.82 billion, a 1.2% year-over-year increase. It also topped the consensus Wall Street analysts' revenue estimate of $2.74 billion.

The company announced a Q1 net loss of $317.2 million, or $3.27 per share, based on generally accepted accounting principles (GAAP). This reflected a steep decline from the GAAP net income of $185.6 million, or $1.86 per share, recorded in the same quarter of 2019.

On a non-GAAP adjusted basis, LabCorp's net income in the first quarter was $2.37 per share. Although this result was well below the adjusted earnings of $2.62 per share posted in the prior-year period, it handily beat the average analysts' adjusted earnings estimate of $1.95 per share.

Behind the numbers

LabCorp's total Q1 revenue increased because of acquisitions. However, sluggish organic growth largely offset the gains from the company's acquisitions. Lower Medicare and Medicaid pricing also weighed down revenue growth.

The company's Covance drug development segment performed relatively well in the first quarter, with revenue rising 6.4% year over year to $1.07 billion. Acquisitions generated revenue growth of 6.2%. Covance's organic revenue grew by 1.6%. But the sale of a business offset this growth by around 1.2%, with currency fluctuations negatively impacting growth by another 0.1%.

LabCorp's diagnostics segment, on the other hand, didn't fare as well in Q1. Revenue for the segment fell 1.2% year over year to $1.72 billion. The primary factors behind this decline were the negative impact of the COVID-19 pandemic and lower Medicare and Medicaid pricing.

COVID-19 also was the main reason for the company's GAAP earnings decline. LabCorp stated that the economic conditions spurred by the viral outbreak caused it to record an impairment of $437.4 million to goodwill and other assets. In addition, the company incurred $21.9 million in other costs related to COVID-19.

LabCorp said that it started off 2020 on a positive footing. However, the demand for diagnostic testing plunged by at least 50% from normal levels at the end of the first quarter due to the COVID-19 pandemic. Covance was also negatively impacted by the COVID-19 outbreak as some clients slowed clinical trials.

Looking ahead

Some healthcare stocks won't be affected all that much by the COVID-19 pandemic, but it's a different story for LabCorp. Because of the uncertainty surrounding the impact of the coronavirus crisis, LabCorp withdrew its full-year 2020 guidance. The company also has temporarily suspended its share repurchase program.

CEO Adam Schechter, though, said, "Looking forward, despite the unpredictability of this health crisis, we are well positioned financially and strategically to continue to serve our customers and drive long-term shareholder value." LabCorp stated that it continues to expect to generate "solid" adjusted earnings per share and free cash flow this year.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Laboratory Corporation of America Stock Quote
Laboratory Corporation of America
$210.27 (-2.21%) $-4.76

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.